Your browser doesn't support javascript.
loading
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury, Habib; Lee, David J; Alberge, Jean-Baptiste; Redd, Robert; Cea-Curry, Christian J; Perry, Jacqueline; Barr, Hadley; Murphy, Ciara; Sakrikar, Dhananjay; Barnidge, David; Bustoros, Mark; Leblebjian, Houry; Cowan, Anna; Davis, Maya I; Amstutz, Julia; Boehner, Cody J; Lightbody, Elizabeth D; Sklavenitis-Pistofidis, Romanos; Perkins, Mark C; Harding, Stephen; Mo, Clifton C; Kapoor, Prashant; Mikhael, Joseph; Borrello, Ivan M; Fonseca, Rafael; Weiss, Scott T; Karlson, Elizabeth; Trippa, Lorenzo; Rebbeck, Timothy R; Getz, Gad; Marinac, Catherine R; Ghobrial, Irene M.
Afiliação
  • El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Lee DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cea-Curry CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Murphy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Sakrikar D; The Binding Site, Rochester, MN, USA.
  • Barnidge D; The Binding Site, Rochester, MN, USA.
  • Bustoros M; Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Leblebjian H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cowan A; Alix School of Medicine, The Mayo Clinic, Rochester, MN, USA.
  • Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Amstutz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Perkins MC; The Binding Site Group, Birmingham, UK.
  • Harding S; The Binding Site Group, Birmingham, UK.
  • Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Kapoor P; The Mayo Clinic, Rochester, MN, USA.
  • Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, North Hollywood, CA, USA.
  • Borrello IM; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Fonseca R; Department of Medical Oncology, The Mayo Clinic, Phoenix, AZ, USA.
  • Weiss ST; Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Karlson E; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rebbeck TR; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Getz G; Harvard Medical School, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Lancet Haematol ; 9(5): e340-e349, 2022 May.
Article em En | MEDLINE | ID: mdl-35344689
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Lancet Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos